BUSTED: Mylan billed taxpayers and patients.

In a recent report, Medicare administrators confirmed our suspicions about EpiPen pricing:

By lying to the government, Mylan was padding its profits with taxpayer dollars and ripping off the Medicaid program. At the same time, it jacked up the prices that families pay by 500% and fleeced patients who rely on EpiPens to survive severe allergic reactions.

That’s not OK.

And here’s the good news: The Department of Justice has forced Mylan to pay a $465 million fine. They’ve heard from us loud and clear – when pharmaceutical companies break the rules to put profits before people, we’re going to hold them accountable.

One more thing: EpiPen can’t possibly be the only “misclassified” drug on the market. We’re going to keep investigating, and when we find other companies ripping off patients and bilking taxpayers, we’ll hold them accountable, too.

Ron